Osteosarcoma Market is Set to Rise by 2036 as 8 Emerging Therapies Set to Drive Future Growth

ADCE-D01 is a first-in-class ADC targeting uPARAP, a receptor highly expressed in several mesenchymal malignancies, including osteosarcoma, soft tissue sarcoma, GIST, mesothelioma, and glioblastoma. Its design combines a uPARAP-binding antibody with a protease-cleavable linker and deruxtecan payload.

Preclinical studies have shown significant antitumor activity across multiple models and supported its further clinical development. ADCE-D01 is currently being studied in a multicenter Phase I/II trial evaluating safety, tolerability, and dosing in patients with soft tissue sarcoma across the United States and Europe. The FDA has granted Fast Track and Orphan Drug designations for soft tissue sarcoma.

Conclusion

Osteosarcoma remains an area of significant unmet medical need, particularly for patients with relapsed, metastatic, or refractory disease. Although current management relies heavily on surgery and chemotherapy, the emerging pipeline is introducing innovative approaches, including immunotherapies, ADCs, targeted inhibitors, and metabolic strategies. Candidates such as OST-HER2, tegavivint, DANYELZA, vactosertib, risvutatug rezetecan, PEEL-224, and ADCE-D01 could broaden future treatment choices if clinical studies confirm meaningful efficacy and safety. With the market projected to grow through 2036, continued investment, stronger clinical evidence, and successful regulatory outcomes will be critical to transforming osteosarcoma care and addressing persistent therapeutic gaps worldwide.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us

Abhishek kumar

info@delveinsight.com